•  
  •  
 

Central Asian Problems of Modern Science and Education

Article Title

THE ROLE OF LIPOPROTEINS IN THE DEVELOPMENT OF DIABETIC NEPHROPATHIA IN PATIENTS WITH DIABETES MELLITUS TYPE 2

Abstract

The purpose of the current study was to find out the correlation and cause effect relationship between LDL cholesterol and nephropathy in diabetic population. Type-2 diabetes mellitus is an increasingly common metabolic abnormality associated with microvascular and macrovascular complications. It is also the most common cause of end stage renal disease (ESRD). Lipoprotein (Lp) is a recently discussed important independent and inheritable risk factor for micro and macrovascular complications and also an independent risk factor for the progression of diabetic nephropathy in DM2 patients with overt proteinuria

First Page

173

Last Page

181

References

[1]. Alvin C. Powers; Diabetes mellitus, Harrison‘s principles of internal medicine vol 2. Edited by Braunwald p 2152. [2]. Andrew J Krentz, Clifford J Bailey: Type 2 Diabetes in practice, 2001; p 1-2. [3]. Beckles GLA, Miller GJ, Kirkwood BR, Alexis SD. Ethnicity and other characteristics predictive of CHD in a community principal results of the StJames Survey Trinidad. Int J Epidemiol, 1989; 18: 808-817. [4]. Berg K. A new serum type system in man, the LP system. Acta Patho Microbial Scand, 1963; 59: 369. [5]. Bernadine Healy. Lp joins other serum cholesterol lipoproteins as risk determinant. JAMA, 1989; 261: 2013-14. [6]. Csaszar A, Dieplinger H, Sandholzer C, Karadi J, Juhast E, Drevel H. Plasma lipoprotein concentration and phenotypes diabetes mellitus. Diabetologia, 1993; 36: 47-51. [7]. Dahlen G, The Lp and coronary artery disease. Acta Med Scand (Suppl), 1974; 570: 571. [8]. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int, 2004; 65: 2309-2320. [9]. Ehnolm C, Garoff. Purification and quantification of the human plasma lipoprotein carrying the Lp antigen. Biochem Biophys Acta, 1975; 239: 431. 181 [10]. Genest J Jr, Jenner JL. Prevalence of Lp in excess in coronary heart disease. Am J Cardiol, 1991; 67: 1039-1045. [11]. Greiber S, Kreusel M, Pavenstadt H, Schollmeyer P, Wanner C: Lipoproteininduces glomerular superoxide anion production. Nephrol Dial Transplant, 1997; 12: 1330-1 [12]. K M Prasannakumar, Mala Dharma lingam. Diabetes mellitus-lipid status, significance of Dyslipidemia. LIPIDS-I.C.P. 2002; 137-148. [13]. Parving HH: Diabetic nephropathy: prevention and treatment. Kidney Int, 2001; 60: 2041-2055. [14]. Remuzzi G, Schieppati A, Ruggenenti P: Clinical practice: nephropathy in patients with type 2 diabetes. N Engl J Med, 2002; 346: 1145-1151, [15]. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure and hyperglycemia. Arch Intern Med, 1998; 158: 998-1004. [16]. Schlondroff D.Cellular mechanisms of lipid injury in the glomerulus, Am J Kidney Dis 1993; 22: 279-85. [17]. Song KH, Yoon KH, Kang ML, Cha BY, Lee KW, Son HY, Kang SK: Progression to overt proteinuria in microalbuminuric Koreans with non-insulindependent diabetes mellitus. Diabetes Res Clin Pract, 1998; 42: 117-121, [18]. Samulsson O, Aurell M, Knight-Gibson C, Alaupovic P, Attman P-O. Apolipoprotein-b- containing lipoproteins and the progression of renal insufficiency. Nephron, 1993; 63: 279-85. [19]. Tetsuo Shoji et al.Atherogenic lipoprotein changes in Diabetic nephropathy. Atherosclerosis; 2001; 156: 425-433. [20]. Utermann G. The mysteries of lipoprotein (a). Science, 1989; 246: 904-910. [21]. V Kannan (DM Nephrology). Renal diseases in diabetes mellitus: Type-2 Diabetes Mellitus: 2004; 172-194

This document is currently not available here.

Share

COinS